The clinical and biochemical profiles of patients with IFG
- 22 Downloads
To study the clinical and biochemical profiles across the different ranges of impaired fasting glucose (IFG) based on American Diabetes Association (ADA) and World Health Organization (WHO) criteria. A cross-sectional study was conducted on 149 subjects, of which 63 belonged to group 1 (IFG = 100–110 mg/dl) and 86 to group 2 (IFG = 111–125 mg/dl). Basic anthropometric and clinical examinations were done for all subjects. Data was collected from patient by a questionnaire, which included the history of hypertension and diabetes and other comorbidities and complications. Biochemical profiles including Fasting Plasma Glucose (FPG), Oral Glucose Tolerance Test (OGTT), HbA1c, Fasting insulin levels and Fasting Lipid Profile were measured. Assessment of insulin resistance and beta cell function was done by Homeostasis Model Assessment (HOMA). Data were analysed using SPSS software version 15 and p < 0.05 considered as statistically significant. Family history of diabetes, prevalence of hypertension and higher BMI were noted to be significant higher in group 2 compared to group 1. Clustering of cardiovascular risk factors suggesting metabolic syndrome was also much higher in group 2 (60.5 vs 39.7% p value = 0.012). Impaired glucose tolerance was significantly higher in group 2 (73.3 vs 28.6 p < 0.001) denoting more glycemia. Insulin resistance (HOMA-IR) was significantly higher in group 2 (p = 0.001). Beta cell function (HOMA-β) was also higher in group 2 but not statistically significant (p = 110). In IFG, the higher range of blood sugar 111 to 125 mg/dl is associated with more glycemia, cardiovascular risk factors and insulin resistance. Beta cell function though higher in this group is inadequate to compensate for higher insulin resistance.
KeywordsImpaired fasting glucose Insulin resistance Beta cell function Homeostasis model
Compliance with ethical standards
Conflict of interest
The authors declare that there are no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.World Health Organisation. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20(7):1183–97.Google Scholar
- 7.Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun 1;18(6):499–502.Google Scholar
- 8.Wagner R, Thorand B, Osterhoff MA, Muller G, Bohm A, Meisinger C, et al. Family history of diabetes is associated with higher risk for prediabetes: a multicentre analysis from the German Center for Diabetes Research. Diabetologia. 2013;56(10):2176–80. https://doi.org/10.1007/s00125-013-3002-1.CrossRefGoogle Scholar
- 9.Morio M, Inoue M, Inoue K, Akimoto K. Impaired fasting glucose as an independent risk factor for hypertension among healthy middle-aged Japanese subjects with optimal blood pressure: the Yuport Medical Checkup Centre retrospective cohort study. Diabetol Metab Syndr. 2013;5(1):81. https://doi.org/10.1186/758-5996-5-81.CrossRefGoogle Scholar
- 10.Mohan V, Deepa M, Anjana RM, Lanthorn H, Deepa R. Incidence of diabetes and pre-diabetes in a selected urban south Indian population (CUPS-19). J Assoc Physicians India. 2008;56:152–7.Google Scholar
- 12.Thompson JL, Herman CJ, Allen P, Helitzer DL, Wilson ND, Whyte AN, et al. Associations between body mass index, cardiorespiratory fitness, metabolic syndrome, and impaired fasting glucose in young, urban native American women. Metab Syndr Relat Disord. 2007;5(1):45–54. https://doi.org/10.1089/met.2006.0015.CrossRefGoogle Scholar
- 14.Shweta Sahai DV, Sharma S. Impaired fasting glucose: a study of its prevalence documented at a tertiary care centre of central India and its association with anthropometric variables. J Indian Acad Clin Med. 2011;12(3):187–92.Google Scholar
- 15.Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care. 2010;33(9):2104–9. https://doi.org/10.2337/dc10-0679.CrossRefGoogle Scholar
- 24.Gupta AK, Prieto-Merino D, Dahlöf B, Sever PS, Poulter NR. Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach. Diabet Med. 2011;28(8):941–7.CrossRefGoogle Scholar